Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
Public ClinicalTrials.gov record NCT01879319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen.
Study identification
- NCT ID
- NCT01879319
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 164 participants
Conditions and interventions
Conditions
Interventions
- Evolocumab AI/pen Biological
- Evolocumab AMD Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 10, 2013
- Primary completion
- Nov 14, 2013
- Completion
- Not listed
- Last update posted
- Nov 29, 2022
Started 2013
United States locations
- U.S. sites
- 22
- U.S. states
- 12
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85020 | — |
| Research Site | Encino | California | 91436 | — |
| Research Site | Thousand Oaks | California | 91360 | — |
| Research Site | Tustin | California | 92780 | — |
| Research Site | Ventura | California | 93003 | — |
| Research Site | Port Charlotte | Florida | 33952 | — |
| Research Site | Saint Augustine | Florida | 32086 | — |
| Research Site | Atlanta | Georgia | 30328 | — |
| Research Site | Atlanta | Georgia | 30342 | — |
| Research Site | Gainesville | Georgia | 30501 | — |
| Research Site | Lexington | Kentucky | 40504 | — |
| Research Site | Lewiston | Maine | 04240 | — |
| Research Site | Ayer | Massachusetts | 01432 | — |
| Research Site | Manlius | New York | 13104 | — |
| Research Site | Cadiz | Ohio | 43907 | — |
| Research Site | Marion | Ohio | 43302 | — |
| Research Site | Duncansville | Pennsylvania | 16635 | — |
| Research Site | Lansdale | Pennsylvania | 19446 | — |
| Research Site | Jackson | Tennessee | 38305 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Austin | Texas | 78731 | — |
| Research Site | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01879319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 29, 2022 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01879319 live on ClinicalTrials.gov.